Connacht Asset Management’s United Therapeutics UTHR Stock Holding History

Connacht Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$306K	Sell	1,356 -1,330	-50%	-$306K	1.82%	27
2023 Q2	$593K	Buy	2,686 +639	+31%	+$142K	0.81%	22
2023 Q1	$458K	Buy	2,047 +589	+40%	+$145K	0.2%	75
2022 Q4	$405K	Sell	1,458 -529	-27%	-$134K	0.18%	78
2022 Q3	$416K	Sell	1,987 -5,431	-73%	-$1.21M	0.3%	80
2022 Q2	$1.75M	Buy	+7,418	New	+$1.51M	0.73%	26

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Connacht Asset Management's UTHR Position: Q3 2023 in Review

Connacht Asset Management reduced its United Therapeutics (UTHR) stake by 50% in Q3 2023, selling an estimated $306K and leaving 1,356 shares worth $306K. The position accounts for 1.82% of the portfolio, ranked #27.

Connacht Asset Management first reported a position in UTHR in Q2 2022 and has held it in 6 quarters since. The position peaked at $1.75M in Q2 2022. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

Connacht Asset Management held 1,356 shares of United Therapeutics worth $306K as of Q3 2023.
Connacht Asset Management sold 1,330 United Therapeutics shares in Q3 2023, an estimated $306K.
United Therapeutics made up 1.82% of Connacht Asset Management's portfolio in Q3 2023, its #27 holding.
Connacht Asset Management first reported a position in United Therapeutics in Q2 2022 and has held it in 6 quarters since.
Connacht Asset Management's United Therapeutics position peaked at $1.75M in Q2 2022.
508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on Connacht Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.